Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
October 25, 2023 06:30 ET
|
Beam Therapeutics
Single Dose of BEAM-301 Restored Clinically Meaningful Endpoints in In Vivo Rodent Disease Models Out to at Least One Year Company Plans to Submit U.S. Investigational New Drug (IND) Application for...
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline
October 19, 2023 08:45 ET
|
Beam Therapeutics
Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to...
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
September 07, 2023 10:00 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new...
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
September 05, 2023 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced...
Beam Therapeutics to Participate in Upcoming September Investor Conferences
August 31, 2023 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
August 08, 2023 06:30 ET
|
Beam Therapeutics
BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort First Patient Consented in Phase 1/2 Trial of...
Beam Therapeutics to Participate in Upcoming May Investor Conferences
May 17, 2023 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
May 11, 2023 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
May 10, 2023 06:30 ET
|
Beam Therapeutics
Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives Multiple Sites...
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
March 27, 2023 07:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...